Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B

NCT01027364 is registered in ClinicalTrials.gov with Bioverativ Therapeutics Inc. as lead sponsor.

NCT NCT01027364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01027364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B
Lead sponsor
Bioverativ Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2009
Completion date
July 31, 2012
Enrollment
123 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia b